- Home
- LFCR vs PEPG Comparison
LFCR vs PEPG Comparison
Compare LFCR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFCR | PEPG |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.0M | 317.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | LFCR | PEPG |
|---|---|---|
| Price | $8.30 | $5.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.00 | ★ $9.50 |
| AVG Volume (30 Days) | 172.3K | ★ 696.9K |
| Earning Date | 01-02-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $128,867,000.00 | N/A |
| Revenue This Year | $2.80 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.47 | N/A |
| 52 Week Low | $4.76 | $0.88 |
| 52 Week High | $8.85 | $6.72 |
Technical Indicators
Market Signals| Indicator | LFCR | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 58.32 |
| Support Level | $7.85 | $5.19 |
| Resistance Level | $8.77 | $6.72 |
| Average True Range (ATR) | 0.36 | 0.41 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 63.64 | 89.47 |
Price Performance
Historical ComparisonAbout LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.